ÀÎÅ©·çÆ®
ÅëÇÕ°Ë»ö
°Ë»ö
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
°³ÀÎȸ¿ø
°³ÀÎȸ¿øȨ
À̷¼ µî·Ï
°ü¸®
ÀÔ»çÁö¿ø°ü¸®
¸¶ÀÌÇÍ
½ºÅ©·¦Á¤º¸
°ü½É±â¾÷Á¤º¸
ÀÎÁõ(À̷¼¹îÁö)
Ãë¾÷Áö¿ø¼ºñ½º
ȸ¿øÁ¤º¸°ü¸®
±â¾÷ȸ¿ø
±â¾÷ Ȩ
¼ºñ½º ¼Ò°³
°ø°íµî·Ï
°ø°í°ü¸®
ÀÎÀç°Ë»ö
½º¸¶Æ®¸ÅĪ
ÀλçºñÁîÀÚ·á
°áÁ¦/ÀÌ¿ë³»¿ª
ȸ¿øÁ¤º¸°ü¸®
ÅëÇÕ°Ë»ö
ä¿ëÁ¤º¸
±â¾÷Á¤º¸
ÀÚ·á½Ç
ä¿ëÁ¤º¸
(ÁÖ)µå¸²¾¾¾ÆÀÌ¿¡½º
°ü½É±â¾÷
KOSDAQ
[µå¸²¾¾¾ÆÀÌ¿¡½º] LPS PM (Project Manager) ä¿ë
½ºÅ©·¦
7~15³â
Çз¹«°ü
¼¿ï>Á¾·Î±¸
Á¤±ÔÁ÷
Ç°Áú°ü¸®,
¼¶À¯¡¤ÈÇÐ,
¹ÙÀÌ¿À¡¤½ÄÇ°°øÇÐ
ä¿ë½Ã
(10ÀÏÀü µî·Ï)
(ÁÖ)µå¸²¾¾¾ÆÀÌ¿¡½º
°ü½É±â¾÷
KOSDAQ
[µå¸²¾¾¾ÆÀÌ¿¡½º] LPS CRA °æ·Â ä¿ë
½ºÅ©·¦
1³â¡è
Çз¹«°ü
¼¿ï>Á¾·Î±¸
Á¤±ÔÁ÷
¾à¹«¡¤Á¦¾à,
Á¶»ç¡¤ºÐ¼®¡¤Åë°è,
°Ç¼³ÇöÀå
ä¿ë½Ã
(10ÀÏÀü µî·Ï)
(ÁÖ)µå¸²¾¾¾ÆÀÌ¿¡½º
°ü½É±â¾÷
KOSDAQ
[µå¸²¾¾¾ÆÀÌ¿¡½º] PVPL(PharmacoVigilance Project Leader) ä¿ë
½ºÅ©·¦
4³â¡è
´ëÁ¹ÀÌ»ó
¼¿ï>Á¾·Î±¸
Á¤±ÔÁ÷
Àü»ê¡¤IT±â¼úÁö¿ø,
¿µ¾÷°ü¸®¡¤¿µ¾÷Áö¿ø,
ÀϹݻ繫¡¤»ç¹«Áö¿ø
ä¿ë½Ã
(10ÀÏÀü µî·Ï)
±Ý¼º1±ÞÀÚµ¿Â÷°ø¾÷»ç
ÀÚµ¿Â÷ °æÁ¤ºñ
½ºÅ©·¦
5³â¡è
°íÁ¹
°æ±â>¿À»ê½Ã
Á¤±ÔÁ÷
¿ù±Þ 4,000,000¿ø
¼³Ä¡¡¤¼ö¸®¡¤Á¤ºñ¡¤A/S
~04.30 (È)
(11ÀÏÀü µî·Ï)
¹ë·ùÀνº
°ü½É±â¾÷
º¥Ã³±â¾÷
ÀǾàÇ°ºñÀÓ»ó ¿¬±¸°³¹ß ½ÅÀÔ/°æ·Â ä¿ë
½ºÅ©·¦
½ÅÀÔ/(¿¬Â÷¹«°ü)
¼®»çÀÌ»ó
°æ±â>¼º³²½Ã ºÐ´ç±¸
Á¤±ÔÁ÷
¼¶À¯¡¤ÈÇÐ
ä¿ë½Ã
(2023.11.08 µî·Ï)
¹Ù·ÎÁö¿ø
ä¿ëÁ¤º¸ ´õº¸±â
±â¾÷Á¤º¸
¾ÆÀÌ¿¡½ººñ
°ü½É±â¾÷
Áß¼Ò±â¾÷
Àü±â¡¤ÀüÀÚ¡¤¹ÝµµÃ¼
°æ±âµµ ½ÃÈï½Ã »ê±â´ëÇзΠ76 (Á¤¿Õµ¿,´ëµ¿»ê¾÷) ¸¶µ¿ 4È£
¼³¸³ÀÏ
2011. 11. 30
´ëÇ¥ÀÚ¸í
À±º¹·¡
¸ÅÃâ¾×
64¾ï 570¸¸¿ø(2022)
ÀÚº»±Ý
1¾ï 9100¸¸¿ø
»ç¿ø¼ö
23 ¸í ÀçÁ÷Áß
Æò±Õ¿¬ºÀ
5,165¸¸¿ø
¾ÆÀÌ¿¡½ººñ
°ü½É±â¾÷
Áß¼Ò±â¾÷
¼Ò¸Å
´ë±¸ µ¿±¸ µ¿È£·Î 75 (½Å¼µ¿)
¼³¸³ÀÏ
2013. 08. 01
´ëÇ¥ÀÚ¸í
ÀÓ¹æÅÃ
¸ÅÃâ¾×
26¾ï 1127¸¸¿ø(2021)
ÀÚº»±Ý
9¾ï 5189¸¸¿ø
»ç¿ø¼ö
-
Æò±Õ¿¬ºÀ
-
±â¾÷Á¤º¸ ´õº¸±â
ÀÔ»çÁö¿øÇϸé ÁÁÀº ÀÌÀ¯
°ø±â¾÷ in ¼¿ï
KOSDAQ »óÀå
½ÅÀÔ¿¬ºÀÀÌ 4õÀÌ»ó
½ºÅ¸Æ®¾÷ ÃʺÀ 3,500¸¸¿ø¢Ö
Áö±Ý HOTÇÑ Ã¤¿ë
±â¾Æ
Çѱ¹¿¡³ÊÁö±â¼ú¿¬±¸¿ø
(ÁÖ)Á¦ÁÖÇ×°ø
(Àç)´ëÀüÀÏÀÚ¸®°æÁ¦ÁøÈï¿ø
(Àç)¼¿ï°æÁ¦ÁøÈï¿ø
Çѱ¹¾ð·ÐÁøÈïÀç´Ü
(Àç)¿À¼Û÷´ÜÀÇ·á»ê¾÷ÁøÈïÀç´Ü
°úÇбâ¼úÀΰøÁ¦È¸
µÎ¼Û°Ç¼³(ÁÖ)
(ÁÖ)ºñ»ó±³À°
¸ÇÀ§·Î